GoCheck builds GoCheck Kids, a digital vision screening platform used by pediatric teams to prevent vision impairment and blindness in children. The platform is FDA-registered and CE-certified. GoCheck serves 6,500 pediatric teams at hospitals, private practices, schools, and screening organizations across three continents. Led by CEO Kevon Saber, the company focuses on supporting pediatric teams in early detection of vision problems. GoCheck intends to use new funding to grow its team, expand the platform, and deepen customer partnerships. GoCheck Kids offers an iPhone photoscreening app that captures images of children’s eyes and uses proprietary algorithms to detect amblyopia risk factors, delivering immediate results to clinicians. The app is FDA-registered and CE-certified and is used by over 4,500 pediatricians. GoCheck Kids says it reduces screening costs by over 60% versus traditional hardware and bills insurers under CPT codes 99177 and 99174; pricing starts at $149 per month per phone. The company highlights endorsements from the American Academy of Pediatrics, the American Academy of Pediatric Ophthalmology and Strabismus, and the American Academy of Ophthalmology. Co-founder David Huang, MD, PhD, who co-invented OCT, leads innovation for the product. Future plans include adding AI capabilities using Apple’s CoreML and ARKit and accelerating electronic health record integrations. Gobiquity develops mobile vision screening applications, with its flagship GoCheck Kids combining photoscreening and digital visual acuity in a single app. GoCheck Kids, launched in 2015, is used by more than 2,000 U.S. pediatricians to identify amblyopia risk factors. The company has surpassed 100,000 screenings and now averages over 3,000 children screened per week, representing over 300% annual growth. Gobiquity recently released a new iPhone app for health care providers and plans to extend the product to caregivers and into adult primary care. Management says it is committed to evolving a validated, portable, and affordable mobile screening portfolio to address both children and adults. The company positions its tools as enabling early detection and prevention of vision impairment.

Total raised

$22M

Funding rounds

3

Latest round

Equity

Latest activity

Oct 2021